Lexeo Therapeutics(LXEO)

Search documents
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Newsfilter· 2024-05-07 11:30
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May ...
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Newsfilter· 2024-04-22 11:30
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions Together with Lexeo Therapeutics' ongoing study of LX2006, a total of 11 participants have been treated to date; includes patients at treatment durations out to 18-months with no treatment-related serious adverse events observed across either study Interim readout of ...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy
Newsfilter· 2024-04-16 11:30
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company's AAVrh.10hFXN-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy. LX2006 is designed to deliver a func ...
Lexeo Therapeutics(LXEO) - 2023 Q4 - Annual Results
2024-03-11 20:11
Exhibit 99.1 Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, showing positive change in post-treatmen ...
Lexeo Therapeutics(LXEO) - 2023 Q4 - Annual Report
2024-03-11 13:29
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-41855 LEXEO THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation ...
Lexeo Therapeutics(LXEO) - 2023 Q3 - Quarterly Report
2023-12-11 12:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41855 Lexeo Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 85-4012572 | | --- | --- | ...